Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Minerva Neurosciences, Inc
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
August 06, 2024
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
May 01, 2024
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
February 27, 2024
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
February 22, 2024
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
November 07, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
August 01, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
June 28, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
May 15, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 10, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
May 08, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 01, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
March 08, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
March 01, 2023
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
December 28, 2022
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 09, 2022
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
November 02, 2022
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
October 17, 2022
From
Minerva Neurosciences, Inc
Via
GlobeNewswire
Tickers
NERV
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.